DEMO: Disease Theme

Women need to empower themselves about the benefits and risks of mammography and examine the additional screening tools available today. One current philosophy suggests breast health screening should begin at age 25. Where does this recommendation come from and why is this valid?

For MOST women, the recommendation for annual breast cancer screening begins at the age of 40. Unfortunately, the American Cancer Society stated that the number one cause of death in women between the ages of 40-44 is breast cancer. So what does this mean for women? It means that we screen at age 40 and potentially find tumors that have been growing for an estimated 8-10 years. Mammography, like most conventional tests, evaluates structure.

There exists a technology that can detect an issue YEARS before a tumor can be seen on X-ray or palpated during an exam. This technology has been approved by the FDA as an adjunctive screening tool since 1982 and offers NO RADIATION, NO COMPRESSION AND NO PAIN. For women who are refusing to have a mammogram or those who want clinical correlation for an existing problem, digital infrared thermal imaging may be of interest.

In November 2003, the American Cancer Society stated that breast cancer is the leading cause of death in women between the ages of 40 and 44. In the United States, there are approximately 200,000 new cases of breast cancer and more than 40,000 deaths; making the U.S. one of the countries with the highest death rate due to breast cancer. Perhaps the most alarming statistic is 1: 8 women will eventually develop breast cancer over their lifetime.

One of the most powerful steps a woman can take to reduce her risk for developing breast cancer is to educate herself about the petrochemicals, or xenoestrogens that are in her environment and work to eliminate or reduce them. Petrochemicals are "hormone disruptors" and it is through the unbalancing of your hormone system that can lead to problems. These xenoestrogens are found in cosmetics, lotions and fingernail polish and polish remover. They are obviously found in pesticides and insecticides. What you may not be aware of is that petrochemicals are found in plastics. If food is placed in a plastic container and reheated in the microwave, the plastic melts into your food and you ingest it. The harder the plastic, the more resistant it is to this process but the potential for accidental xenoestrogen ingestion is still present. Simply put, do not reheat food in plastic containers in the microwave.

I had been a bit nervous all day wondering what my thermogram procedure would entail. Would I need to undress completely? Would I be given one of those paper gowns that opens in the front and barely covers me? Would there be any heat coming out of the camera? I had been avoiding a mammogram after reading the latest information about the risks associated with X-ray; knowing that I was potentially putting myself at greater risk by not taking charge of my health. It was my massage therapist who told me about thermography as an adjunctive tool for breast cancer screening and now I find myself lost in my thoughts as I am driving to my thermographic appointment.

As I entered the lobby, I noticed that the temperature was cool and refreshing. The paintings on the wall were bright and cheerful with many colors that caught my eye. I felt at ease right away.

It is generally accepted that by the time a cancer is found by mammography or palpated during a clinical breast exam, the cancer has been growing for 8-10 years. What if we could have been alerted to the problem as it was developing, rather than wait till it is large enough to be seen by the naked eye? Would that be of interest to you?

There exists a technology that can detect an issue YEARS before a tumor can be seen on X-ray or palpated during an exam. This technology has been approved by the FDA as an adjunctive screening tool since 1982 and offers NO RADIATION, NO COMPRESSION AND NO PAIN. For women who are refusing to have a mammogram or those who want clinical correlation for an existing problem, digital infrared thermal imaging may be of interest.

There are very strict protocols both for testing and interpreting. Perhaps due to these guidelines, thermography (as with all digital technology) has exploded in its technique and capabilities. Thermal cameras detect heat emitted from the body and display it as a picture on a computer monitor. These images are unique to the person and remain stable over time. It is because of these characteristics that thermal imaging is a valuable and effective screening tool. Tumors or other breast diseases measures warmer than surrounding tissue and can thereby alert a physician to a problem before a tumor is actually palpable.

Digital technology now makes Digital Infrared Thermal Imaging available to all. There now is a completely safe test that can aid in diagnosis, treatment and monitoring with absolutely no risk or radiation exposure.

DITI, or digital infrared thermal imaging, is a noninvasive diagnostic test that allows a health practitioner to see and measure changes in skin surface temperature. An infrared scanning camera translates infrared radiation emitted from the skin surface and records them on a color monitor. This visual image graphically maps the body temperature and is referred to as a thermogram. The spectrum of colors indicates an increase or decrease in the amount of infrared radiation being emitted from the body surface. In healthy people, there is a symmetrical skin pattern which is consistent and reproducible for any individual.

DITI is highly sensitive and can therefore be used clinically to detect disease in the vascular, muscular, neural and skeletal systems. Medical DITI has been used extensively in human medicine in the United States, Europe and Asia for the past 20 years. Until now, bulky equipment has hindered its diagnostic and economic feasibility. Now, PC-based infrared technology designed specifically for clinical application has changed all this.

In the United States, American women are told to begin annual mammographic screening for breast cancer at the age of 40. Long before we’ve reached this age, we are advised to perform a monthly breast exam and see our doctors for a clinical breast exam (CBE) annually as well. However, the detection rate of breast cancer for CBE is only 47% when the tumors are less than 1 centimeter while mammography has given us a 70% detection rate. By the time a tumor is detected by palpation or found mammographically, it has already been growing and developing for 8-10 years.

Mammography has a high false positive rate. Only 1:6 biopsies are found to be positive for cancer when performed due to a positive mammogram or CBE. This places additional stressors on women who undergo these procedures.

Who would have thought that a technology for detecting breast cancer used today actually had its’ roots dating back to 480 B.C.? Digital Infrared Thermal Imaging (DITI) is a fairly new technology that represents a practice that was once used by Hippocrates. This technology is based on a technique that Hippocrates would use as he spread mud over his patients and then watched to see which areas dried first. It was in those places on the body that could show a disease.

It wasn’t until 1957 that the first modern application of thermography came into existence when a Canadian doctor discovered that the skin temperature over a breast tumor was higher than that of healthy tissue. By 1982, the Food and Drug Administration approved thermography and classified it as an additional diagnostic tool for the detection of breast cancer. However, DITI was introduced as a diagnostic tool before strict protocols were established for both the technicians who performed the scans and the doctors who interpreted the scans. Shortly after its initial beginnings, DITI fell out of favor as a diagnostic tool in the medical community.

Most women are familiar with mammography as our “gold standard” for breast cancer screening. However, there are additional tools available that women can add to their arsenal.

One of the most effective tools in breast cancer screening is breast self-exam (BSE). However, BSE works best when women are appropriately trained in the procedure, and then followed-up with annual clinical breast exams (CBE) from their physicians. In a 2000 University of Toronto study, approximately 20,000 women were screened for breast cancer with BSE and annual CBE, and 20,000 were screened with BSE and mammograms. After more than 10 years, the BSE and annual CBE reported 610 cases of invasive breast cancer, and 105 deaths. In the BSE and mammogram group, there were 622 cases of invasive breast cancer and 107 deaths. Without question, the first line of defense against breast cancer begins with diligent BSE.

Other tools that are available to women include the AMAS (anti-malignan antibody screen) test and the NMP Nuclear matrix protein) test. Both these are blood tests that measure a certain protein in the blood that may indicate cancer. The AMAS test has been around for several years while the NMP test has not been available until only recently. Clinical trials continue in this area.

Who isn’t familiar with the expression, "early detection is the best prevention?" We hear this term throughout the year and most everyone is familiar with this "catch phrase" as it relates to breast cancer. Obviously, a woman’s chance for survival improves when a cancer is found early. We hear that simple rhyming statement but are women really offered early detection?

Our "gold standard" for breast cancer screening is mammography, clinical breast exam and self-breast exam. Other techniques are used but ALL current technologies examine structure; something is formed and large enough to be seen or felt. However, it is well-documented that a mass that is detected by mammography has been growing for 8-10 years before it was detected. Is this early detection?

There exists a technology that can detect an issue YEARS before a tumor can be seen on X-ray or palpated during an exam and truly offers early detection. This technology has been approved by the FDA as an adjunctive screening tool since 1982 and offers NO RADIATION, NO COMPRESSION AND NO PAIN. For women who are searching for early breast cancer detection, digital infrared thermal imaging (DITI) may be of interest.

How much chemotherapy does an obese woman need? Typically an obese woman with breast cancer would receive reduced doses of chemotherapy as they battle breast cancer.

Back in June of 2005, a study published in the Archives of Internal Medicine concluded that obese women should receive chemotherapy based on their actual weight, and not in reduced as amounts as it the standard practice.

And now again a study presented in the August 2005 edition of Lancet claims that doctors should not reduce chemotherapy doses for obese women when no receptors for the hormone oestrogen have been found on the breast cancer cells. This type of cancer is called oestrogen-receptor negative.

Clinicians often reduce chemotherapy doses for obese patients because of worries about how the treatment may react with the patient and affect their overall health.

According to the study’s director Marco Colleoni of the European Institute of Oncology, Italy, and his colleagues, reducing the first course of chemotherapy for obese patients with oestrogen-receptor negative breast cancer proves "detrimental".

Colleoni and his team looked at the relation between body-mass index (BMI), chemotherapy dose reduction, oestrogen receptor expression, and outcome for pre-menopausal women with breast cancer by examining data from four randomized trials.